↓ Skip to main content

Life expectancy of HIV-positive individuals on combination antiretroviral therapy in Canada

Overview of attention for article published in BMC Infectious Diseases, July 2015
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (90th percentile)
  • High Attention Score compared to outputs of the same age and source (88th percentile)

Mentioned by

policy
1 policy source
twitter
18 X users
facebook
1 Facebook page
googleplus
2 Google+ users

Citations

dimensions_citation
107 Dimensions

Readers on

mendeley
142 Mendeley
citeulike
1 CiteULike
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Life expectancy of HIV-positive individuals on combination antiretroviral therapy in Canada
Published in
BMC Infectious Diseases, July 2015
DOI 10.1186/s12879-015-0969-x
Pubmed ID
Authors

Sophie Patterson, Angela Cescon, Hasina Samji, Keith Chan, Wendy Zhang, Janet Raboud, Ann N. Burchell, Curtis Cooper, Marina B. Klein, Sean B. Rourke, Mona R. Loutfy, Nima Machouf, Julio S. G. Montaner, Chris Tsoukas, Robert S. Hogg, CANOC collaboration

Abstract

We sought to evaluate life expectancy and mortality of HIV-positive individuals initiating combination antiretroviral therapy (ART) across Canada, and to consider the potential error introduced by participant loss to follow-up (LTFU). Our study used data from the Canadian Observational Cohort (CANOC) collaboration, including HIV-positive individuals aged ≥18 years who initiated ART on or after January 1, 2000. The CANOC collaboration collates data from eight sites in British Columbia, Ontario, and Quebec. We computed abridged life-tables and remaining life expectancies at age 20 and compared outcomes by calendar period and patient characteristics at treatment initiation. To correct for potential underreporting of mortality due to participant LTFU, we conservatively estimated 30 % mortality among participants lost to follow-up. 9997 individuals contributed 49,589 person-years and 830 deaths for a crude mortality rate of 16.7 [standard error (SE) 0.6] per 1000 person-years. When assigning death to 30 % of participants lost to follow-up, we estimated 1170 deaths and a mortality rate of 23.6 [SE 0.7] per 1000 person-years. The crude overall life expectancy at age 20 was 45.2 [SE 0.7] and 37.5 [SE 0.6] years after adjusting for LTFU. In the LTFU-adjusted analysis, lower life expectancy at age 20 was observed for women compared to men (32.4 [SE 1.1] vs. 39.2 [SE 0.7] years), for participants with injection drug use (IDU) history compared to those without IDU history (23.9 [SE 1.0] vs. 52.3 [SE 0.8] years), for participants reporting Aboriginal ancestry compared to those with no Aboriginal ancestry (17.7 [SE 1.5] vs. 51.2 [SE 1.0] years), and for participants with CD4 count <350 cells/μL compared to CD4 count ≥350 cells/μL at treatment initiation (36.3 [SE 0.7] vs. 43.5 [SE 1.3] years). Life expectancy at age 20 in the calendar period 2000-2003 was lower than in periods 2004-2007 and 2008-2012 in the LTFU-adjusted analyses (30.8 [SE 0.9] vs. 38.6 [SE 1.0] and 54.2 [SE 1.4]). Life expectancy and mortality for HIV-positive individuals receiving ART differ by calendar period and patient characteristics at treatment initiation. Failure to consider LTFU may result in underestimation of mortality rates and overestimation of life expectancy.

X Demographics

X Demographics

The data shown below were collected from the profiles of 18 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 142 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 142 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 29 20%
Researcher 18 13%
Student > Bachelor 17 12%
Student > Ph. D. Student 10 7%
Other 10 7%
Other 31 22%
Unknown 27 19%
Readers by discipline Count As %
Medicine and Dentistry 59 42%
Agricultural and Biological Sciences 12 8%
Nursing and Health Professions 9 6%
Social Sciences 7 5%
Immunology and Microbiology 5 4%
Other 13 9%
Unknown 37 26%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 18. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 December 2018.
All research outputs
#1,842,319
of 23,905,714 outputs
Outputs from BMC Infectious Diseases
#489
of 7,959 outputs
Outputs of similar age
#21,852
of 237,283 outputs
Outputs of similar age from BMC Infectious Diseases
#18
of 149 outputs
Altmetric has tracked 23,905,714 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 7,959 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.5. This one has done particularly well, scoring higher than 93% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 237,283 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 149 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 88% of its contemporaries.